186 related articles for article (PubMed ID: 34923340)
1. Impaired bone marrow microenvironment and stem cells in transfusion-dependent beta-thalassemia.
Zhou X; Huang L; Wu J; Qu Y; Jiang H; Zhang J; Qiu S; Liao C; Xu X; Xia J; Lian Q
Biomed Pharmacother; 2022 Feb; 146():112548. PubMed ID: 34923340
[TBL] [Abstract][Full Text] [Related]
2. Bone marrow stromal cells from β-thalassemia patients have impaired hematopoietic supportive capacity.
Crippa S; Rossella V; Aprile A; Silvestri L; Rivis S; Scaramuzza S; Pirroni S; Avanzini MA; Basso-Ricci L; Hernandez RJ; Zecca M; Marktel S; Ciceri F; Aiuti A; Ferrari G; Bernardo ME
J Clin Invest; 2019 Feb; 129(4):1566-1580. PubMed ID: 30830876
[TBL] [Abstract][Full Text] [Related]
3. Management of Iron Overload in Beta-Thalassemia Patients: Clinical Practice Update Based on Case Series.
Pinto VM; Forni GL
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33233561
[TBL] [Abstract][Full Text] [Related]
4. New therapeutic targets in transfusion-dependent and -independent thalassemia.
Cappellini MD; Motta I
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):278-283. PubMed ID: 29222267
[TBL] [Abstract][Full Text] [Related]
5. Bone marrow mesenchymal stem cells in patients with beta thalassemia major: molecular analysis with attenuated total reflection-Fourier transform infrared spectroscopy study as a novel method.
Aksoy C; Guliyev A; Kilic E; Uckan D; Severcan F
Stem Cells Dev; 2012 Jul; 21(11):2000-11. PubMed ID: 22214206
[TBL] [Abstract][Full Text] [Related]
6. ROS-mediated iron overload injures the hematopoiesis of bone marrow by damaging hematopoietic stem/progenitor cells in mice.
Chai X; Li D; Cao X; Zhang Y; Mu J; Lu W; Xiao X; Li C; Meng J; Chen J; Li Q; Wang J; Meng A; Zhao M
Sci Rep; 2015 May; 5():10181. PubMed ID: 25970748
[TBL] [Abstract][Full Text] [Related]
7. β-Thalassemia intermedia: a comprehensive overview and novel approaches.
Asadov C; Alimirzoeva Z; Mammadova T; Aliyeva G; Gafarova S; Mammadov J
Int J Hematol; 2018 Jul; 108(1):5-21. PubMed ID: 29380178
[TBL] [Abstract][Full Text] [Related]
8. The bone marrow hematopoietic microenvironment is impaired in iron-overloaded mice.
Okabe H; Suzuki T; Uehara E; Ueda M; Nagai T; Ozawa K
Eur J Haematol; 2014 Aug; 93(2):118-28. PubMed ID: 24628561
[TBL] [Abstract][Full Text] [Related]
9. Effects of iron overload on the bone marrow microenvironment in mice.
Zhang Y; Zhai W; Zhao M; Li D; Chai X; Cao X; Meng J; Chen J; Xiao X; Li Q; Mu J; Shen J; Meng A
PLoS One; 2015; 10(3):e0120219. PubMed ID: 25774923
[TBL] [Abstract][Full Text] [Related]
10. Alpha- and Beta-thalassemia: Rapid Evidence Review.
Baird DC; Batten SH; Sparks SK
Am Fam Physician; 2022 Mar; 105(3):272-280. PubMed ID: 35289581
[TBL] [Abstract][Full Text] [Related]
11. Iron toxicity - Its effect on the bone marrow.
Isidori A; Borin L; Elli E; Latagliata R; Martino B; Palumbo G; Pilo F; Loscocco F; Visani G; Cianciulli P
Blood Rev; 2018 Nov; 32(6):473-479. PubMed ID: 29699840
[TBL] [Abstract][Full Text] [Related]
12. Management of iron overload before, during, and after hematopoietic stem cell transplantation for thalassemia major.
Angelucci E; Pilo F
Ann N Y Acad Sci; 2016 Mar; 1368(1):115-21. PubMed ID: 26999450
[TBL] [Abstract][Full Text] [Related]
13. Transferrin receptor 2 is a potential novel therapeutic target for β-thalassemia: evidence from a murine model.
Artuso I; Lidonnici MR; Altamura S; Mandelli G; Pettinato M; Muckenthaler MU; Silvestri L; Ferrari G; Camaschella C; Nai A
Blood; 2018 Nov; 132(21):2286-2297. PubMed ID: 30209118
[TBL] [Abstract][Full Text] [Related]
14. 2021 update on clinical trials in β-thalassemia.
Musallam KM; Bou-Fakhredin R; Cappellini MD; Taher AT
Am J Hematol; 2021 Nov; 96(11):1518-1531. PubMed ID: 34347889
[TBL] [Abstract][Full Text] [Related]
15. Hematopoietic stem cell function in β-thalassemia is impaired and is rescued by targeting the bone marrow niche.
Aprile A; Gulino A; Storto M; Villa I; Beretta S; Merelli I; Rubinacci A; Ponzoni M; Marktel S; Tripodo C; Lidonnici MR; Ferrari G
Blood; 2020 Jul; 136(5):610-622. PubMed ID: 32344432
[TBL] [Abstract][Full Text] [Related]
16. Free iron catalyzes oxidative damage to hematopoietic cells/mesenchymal stem cells in vitro and suppresses hematopoiesis in iron overload patients.
Lu W; Zhao M; Rajbhandary S; Xie F; Chai X; Mu J; Meng J; Liu Y; Jiang Y; Xu X; Meng A
Eur J Haematol; 2013 Sep; 91(3):249-261. PubMed ID: 23772810
[TBL] [Abstract][Full Text] [Related]
17. Morbidities in non-transfusion-dependent thalassemia.
Saliba AN; Taher AT
Ann N Y Acad Sci; 2016 Mar; 1368(1):82-94. PubMed ID: 27186941
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of FGF23 is a therapeutic strategy to target hematopoietic stem cell niche defects in β-thalassemia.
Aprile A; Raggi L; Bolamperti S; Villa I; Storto M; Morello G; Marktel S; Tripodo C; Cappellini MD; Motta I; Rubinacci A; Ferrari G
Sci Transl Med; 2023 May; 15(698):eabq3679. PubMed ID: 37256933
[TBL] [Abstract][Full Text] [Related]
19. Ferroportin inhibitor vamifeport ameliorates ineffective erythropoiesis in a mouse model of β-thalassemia with blood transfusions.
Kalleda N; Flace A; Altermatt P; Ingoglia G; Doucerain C; Nyffenegger N; Dürrenberger F; Manolova V
Haematologica; 2023 Oct; 108(10):2703-2714. PubMed ID: 37165842
[TBL] [Abstract][Full Text] [Related]
20. Successful treatment of murine beta-thalassemia intermedia by transfer of the human beta-globin gene.
May C; Rivella S; Chadburn A; Sadelain M
Blood; 2002 Mar; 99(6):1902-8. PubMed ID: 11877258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
